PortalPublikationenCD133 expression in cancer cells predicts poor prognosis of ...

CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma

Standard

CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma. / Cai, Xiaobo; Li, Jun; Yuan, Xiaodong; Xiao, Jingbo; Dooley, Steven; Wan, Xinjian; Weng, Honglei; Lu, Lungen.

in: J TRANSL MED, Jahrgang 16, Nr. 1, 06.03.2018, S. 50.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cai, X, Li, J, Yuan, X, Xiao, J, Dooley, S, Wan, X, Weng, H & Lu, L 2018, 'CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma', J TRANSL MED, Jg. 16, Nr. 1, S. 50. https://doi.org/10.1186/s12967-018-1423-9

APA

Cai, X., Li, J., Yuan, X., Xiao, J., Dooley, S., Wan, X., Weng, H., & Lu, L. (2018). CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma. J TRANSL MED, 16(1), 50. https://doi.org/10.1186/s12967-018-1423-9

Vancouver

Cai X, Li J, Yuan X, Xiao J, Dooley S, Wan X et al. CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma. J TRANSL MED. 2018 Mär 6;16(1):50. https://doi.org/10.1186/s12967-018-1423-9

Bibtex

@article{4062d04c75694395a1c2e8d625b5a722,
title = "CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma",
abstract = "BACKGROUND: CD133 is a marker of stem cells as well cancer stem cells. This study investigated the association between CD133 expression in cancer cells and the clinical outcome of non-mucin producing intrahepatic cholangiocarcinoma (ICC).METHODS: Fifty-seven non-mucin producing ICC patients were enrolled in this study. Immunohistochemistry (IHC) and immunofluorescence staining for CD133 as well as other cancer-associated proteins, including cytokeratin 19, TGF-β1, p-Smad2 and epithelial-mesenchymal transition (EMT) markers S100A4, E-Cadherin and Vimentin were analyzed.RESULTS: IHC staining showed that tumor cells in 52.6% of patients expressed CD133. The CD133+ patients had significantly higher metastasis rate than those without CD133+ tumor cells (36.7% vs. 10.1%, p = 0.03). The CD133+ patients had shorter overall and disease-free survival time as compared to the CD133- patients. Furthermore, 90.9% of CD133+ patients developed cancer recurrence, as compared to 64.3% of CD133- patients (p = 0.02). As compared to CD133- patients, tumor cells in CD133+ patients demonstrated high levels of TGF-β/p-Smad2 as well as EMT-like alteration, characterized by loss of E-Cadherin and expression of Vimentin and S100A4.CONCLUSIONS: CD133 expression in ICC tumor cells indicates poor prognosis of the disease and might be associated with TGF-β related EMT alterations.",
keywords = "AC133 Antigen/metabolism, Biomarkers, Tumor/metabolism, Cholangiocarcinoma/diagnosis, Disease-Free Survival, Epithelial-Mesenchymal Transition, Female, Humans, Male, Middle Aged, Mucins/metabolism, Phenotype, Prognosis, Signal Transduction, Survival Analysis, Transforming Growth Factor beta1/metabolism",
author = "Xiaobo Cai and Jun Li and Xiaodong Yuan and Jingbo Xiao and Steven Dooley and Xinjian Wan and Honglei Weng and Lungen Lu",
year = "2018",
month = mar,
day = "6",
doi = "10.1186/s12967-018-1423-9",
language = "English",
volume = "16",
pages = "50",
journal = "J TRANSL MED",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma

AU - Cai, Xiaobo

AU - Li, Jun

AU - Yuan, Xiaodong

AU - Xiao, Jingbo

AU - Dooley, Steven

AU - Wan, Xinjian

AU - Weng, Honglei

AU - Lu, Lungen

PY - 2018/3/6

Y1 - 2018/3/6

N2 - BACKGROUND: CD133 is a marker of stem cells as well cancer stem cells. This study investigated the association between CD133 expression in cancer cells and the clinical outcome of non-mucin producing intrahepatic cholangiocarcinoma (ICC).METHODS: Fifty-seven non-mucin producing ICC patients were enrolled in this study. Immunohistochemistry (IHC) and immunofluorescence staining for CD133 as well as other cancer-associated proteins, including cytokeratin 19, TGF-β1, p-Smad2 and epithelial-mesenchymal transition (EMT) markers S100A4, E-Cadherin and Vimentin were analyzed.RESULTS: IHC staining showed that tumor cells in 52.6% of patients expressed CD133. The CD133+ patients had significantly higher metastasis rate than those without CD133+ tumor cells (36.7% vs. 10.1%, p = 0.03). The CD133+ patients had shorter overall and disease-free survival time as compared to the CD133- patients. Furthermore, 90.9% of CD133+ patients developed cancer recurrence, as compared to 64.3% of CD133- patients (p = 0.02). As compared to CD133- patients, tumor cells in CD133+ patients demonstrated high levels of TGF-β/p-Smad2 as well as EMT-like alteration, characterized by loss of E-Cadherin and expression of Vimentin and S100A4.CONCLUSIONS: CD133 expression in ICC tumor cells indicates poor prognosis of the disease and might be associated with TGF-β related EMT alterations.

AB - BACKGROUND: CD133 is a marker of stem cells as well cancer stem cells. This study investigated the association between CD133 expression in cancer cells and the clinical outcome of non-mucin producing intrahepatic cholangiocarcinoma (ICC).METHODS: Fifty-seven non-mucin producing ICC patients were enrolled in this study. Immunohistochemistry (IHC) and immunofluorescence staining for CD133 as well as other cancer-associated proteins, including cytokeratin 19, TGF-β1, p-Smad2 and epithelial-mesenchymal transition (EMT) markers S100A4, E-Cadherin and Vimentin were analyzed.RESULTS: IHC staining showed that tumor cells in 52.6% of patients expressed CD133. The CD133+ patients had significantly higher metastasis rate than those without CD133+ tumor cells (36.7% vs. 10.1%, p = 0.03). The CD133+ patients had shorter overall and disease-free survival time as compared to the CD133- patients. Furthermore, 90.9% of CD133+ patients developed cancer recurrence, as compared to 64.3% of CD133- patients (p = 0.02). As compared to CD133- patients, tumor cells in CD133+ patients demonstrated high levels of TGF-β/p-Smad2 as well as EMT-like alteration, characterized by loss of E-Cadherin and expression of Vimentin and S100A4.CONCLUSIONS: CD133 expression in ICC tumor cells indicates poor prognosis of the disease and might be associated with TGF-β related EMT alterations.

KW - AC133 Antigen/metabolism

KW - Biomarkers, Tumor/metabolism

KW - Cholangiocarcinoma/diagnosis

KW - Disease-Free Survival

KW - Epithelial-Mesenchymal Transition

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Mucins/metabolism

KW - Phenotype

KW - Prognosis

KW - Signal Transduction

KW - Survival Analysis

KW - Transforming Growth Factor beta1/metabolism

U2 - 10.1186/s12967-018-1423-9

DO - 10.1186/s12967-018-1423-9

M3 - SCORING: Journal article

C2 - 29510695

VL - 16

SP - 50

JO - J TRANSL MED

JF - J TRANSL MED

SN - 1479-5876

IS - 1

ER -